Beijing Approves Patent For CanSino Vaccine

China's adenoviral vaccine candidate by CanSino Biologics becomes the first COVID-19 vaccine to win a patent approval from Beijing, reported state-owned newspaper People's Daily on Sunday. It cited documents from the country's National Intellectual Property Administration saying that the patent was issued on Aug. 11

Saudi Arabia has stated that it will start Phase III trials for the vaccine while CanSino is also in talks with Russia,Brazil and Chile to launch Phase III trials of the vaccine candidate.